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Abstract
To follow‐up on our previous report that acarbose (ACA), a drug that blocks
postprandial glucose spikes, increases mouse lifespan, we studied ACA at three
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doses: 400, 1,000 (the original dose), and 2,500 ppm, using genetically heterogeneous mice at three sites. Each dose led to a significant change (by log‐rank test) in
both sexes, with larger effects in males, consistent with the original report. There
were no significant differences among the three doses. The two higher doses
produced 16% or 17% increases in median longevity of males, but only 4% or 5%
increases in females. Age at the 90th percentile was increased significantly (8%–
11%) in males at each dose, but was significantly increased (3%) in females only at
1,000 ppm. The sex effect on longevity is not explained simply by weight or fat
mass, which were reduced by ACA more in females than in males. ACA at
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1,000 ppm reduced lung tumors in males, diminished liver degeneration in both
sexes and glomerulosclerosis in females, reduced blood glucose responses to refeeding in males, and improved rotarod performance in aging females, but not males.
Three other interventions were also tested: ursolic acid, 2‐(2‐hydroxyphenyl) benzothiazole (HBX), and INT‐767; none of these affected lifespan at the doses tested.
The acarbose results confirm and extend our original report, prompt further attention to the effects of transient periods of high blood glucose on aging and the diseases of aging, including cancer, and should motivate studies of acarbose and other
glucose‐control drugs in humans.
KEYWORDS

acarbose, health measures, heterogeneous mice, lifespan

1 | INTRODUCTION

does not sequester glucose, nor block its uptake—it blocks its

The ITP finds interventions that improve mammalian lifespan, and

release from complex polysaccharides.

the current study determines optimal doses of ACA. These studies

Like chronic diet restriction (DR), chronic ACA treatment

suggest new insights into the factors that modulate aging rates and

reduces body weight and body fat, and also improves glucose dys-

may lead to treatments useful in the clinic. Such interventions also

regulation associated with aging (Yamamoto & Otsuki 2006). How-

suggest hypotheses for basic research, as different biological systems

ever, unlike DR, food intake is often increased, not reduced, during

are compared, and different models of delayed aging contrasted to

long‐term ACA treatment (Yamamoto & Otsuki 2006). Importantly,

distinguish changes essential in delaying aging.

ACA increases HET3 mouse lifespans more effectively in males

The ITP design, presented at this URL: (http://www.nia.nih.gov/
research/dab/interventions-testing-program-itp),

uses

genetically

heterogeneous (UM‐HET3) mice, the offspring of the CByB6F1 ×

than in females (Harrison et al., 2014; Strong et al., 2016), while
DR increases lifespan to a similar degree in both (Flurkey et al.,
2010).

C3D2F1 cross. Such crosses of two diverse F1 hybrids, representing

Once a longevity study has shown a benefit at the drug dose

four different inbred strains, produce genetically heterogeneous pop-

tested initially, it is very useful to evaluate the same drug over a

ulations in which each animal is unique, but a full sibling of all other

wider range of doses to try to determine the optimal dose for bene-

mice in the population, so that the cross is reproducible (Roderick,

ficial effect. Lower doses could, in principle, be more effective than

1963). Use of genetically diverse individuals minimizes the possibility

the original dose, if the lower dose mitigates harmful side effects.

that characteristics of a single inbred or F1 hybrid genotype might

Doses above the one originally tested could, in principle, be more

be confused with those of the species. The ITP includes replication

effective, if benefits are proportional to drug concentrations over

at three sites, with sufficient mice to give more than 80% power to

the tested range. A drug that led to sex‐specific benefits at the origi-

detect a change of 10% in mean lifespan, even if only two of the

nal dose may, in principle, show strong effects in both sexes, if, for

three sites contribute data. This design was detailed previously (Har-

example, its blood or tissue concentration is affected by sex‐specific

rison et al., 2009, 2014; Miller et al, 2011, 2014; Strong et al., 2008,

metabolic pathways. Better definition of optimal drug dose is also

2013, 2016).

very helpful in providing a foundation for further studies. For these

The interventions for this study were chosen for the following

reasons, three different doses of ACA are tested here.

reasons:
2. Ursolic acid (UA) decreased d‐galactose (D‐gal)‐induced neurotox1. Acarbose (ACA) is a candidate to replicate some aspects of diet

icity in mice (Lu et al., 2007) and also inhibited cognitive impair-

or caloric restriction. Archer (2003) suggests that the postmeal

ment induced by a high‐fat diet (Lu et al., 2011). Kunkel et al.

spike in glucose may contribute to aging. This spike is reduced

(2012) found that UA increased skeletal muscle mass and func-

by ACA (Balfour & McTavish, 1993). Acarbose has been widely

tion while improving glucose tolerance and reducing obesity.

used clinically to prevent postprandial hyperglycemia, and several

These results suggest that UA might benefit deleterious effects

reports (Frantz et al., 2005; Miyamura et al., 2010) demonstrate

of age.

its ability to reduce or prevent postprandial hyperglycemia in
mice. The glucose spike during a meal is blunted because acar-

3. 2‐(2‐hydroxyphenyl) benzothiazole (HBX) is a compound with

bose inhibits α‐glucosidase, thus reducing the rate at which

similar structural features to the flavonoid Thioflavin T (4‐(3,6‐

polysaccharides are digested, as well as reducing sugar uptake. It

dimethyl‐1,3‐benzothiazol‐3‐ium‐2‐yl)‐N,N‐dimethylaniline
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chloride), a molecule used in histopathology to stain amyloid in

Using data pooled across the three sites, ACA had significant effects

tissues. These molecules are able to maintain protein homeostasis

by the log‐rank test on female median lifespans at all three doses. At

during aging, and to increase median and maximal lifespans in

medium and high doses, median lifespan increased 5% (p = 0.003)

C. elegans (Alavez et al., 2011).

and 4% (p = 0.006), respectively. The lowest dose of ACA did not
change median survival (0% increase), but significantly (p = 0.03)

4. INT‐767d

sulfate

improved survival at ages greater than the median (Table 1, Fig-

sodium salt) is a dual FXR/TGR5 activating agonist. Activating the

ure 1a). ACA had much more benefit in males, whose median lifes-

bile acid‐activated nuclear hormone receptor FXR, and the G protein

pans were increased by the three doses by 11%, 17%, and 16%,

coupled receptor TGR5, reduces several diseases of aging, including

respectively, all highly (p < 0.0001) significant (Table 1, Figure 1b).

chronic liver and kidney disease as well as diabetes (Rizzo et al.,

None of the effects on lifespan of the three ACA doses were signifi-

2010). Chronic treatment of aging mice with INT‐767d could, in

cantly different from the other two doses in either males or females.

principle, retard these diseases as well as other deleterious aspects

We used the 90th percentile as a surrogate for maximum lifespan,

of aging (Fiorucci, Mencarelli, Palladino, & Cipriani, 2009; Hylemon

and the Wang/Allison test (Wang, Li, Redden, Weindruch, & Allison,

et al., 2009; Wang et al, 2017). Dwarf mouse models with increased

2004) in pooled data also showed much larger benefits in males. The

lifespan also have increased serum and liver bile acid levels and FXR

low, medium, and high doses of ACA caused increases of 2%, 3%,

activation, which supports this idea (Gems, 2007).

and 3% (p = 0.37, 0.007, 0.10), respectively, in females, and 11%,

(6α‐ethyl‐24‐nor‐5β‐cholane‐3α,7α,23‐triol‐23

11%, and 8% (p = 0.0004, 0.0004, 0.0001), respectively, in males
(Table 1). Neither UA, I767 nor HBX changed lifespan significantly in

2 | RESULTS

either males or females at the doses used.
Site differences showed the importance of replication (Table 2) and

2.1 | Lifespan and body weight

the value of pooling data to increase sample size and statistical power.

Mice were fed ACA at three different doses: low—400, medium—

Effects of ACA were not significant in females at either TJL or UM,

1,000, and high—2,500 mg per kg diet (ppm) from 8 months of age.

although they were at UT ranging from p = 0.02 to 0.03. In males, all

T A B L E 1 Effects of three different doses of ACA on lifespan
Median lifespan

Lifespan at 90th percentile

N

Days

Cont_13

287

889

ACA_lo

139

887

0%

0.03

ACA_mid

142

933

5%

ACA_hi

152

922

4%
0%

Group

% change

p‐value

% change

Wang–Allison p‐value

1,123

2%

0.37

0.003

1,125

3%

0.007

0.006

1,125

3%

0.10

0.49

1,084

–1%

0.46

Days

Females
1,097

UA

147

885

Cont_12

279

877

HBX

136

856

–2%

0.4

1,091

–1%

NS

I767d

136

868

–1%

0.8

1,102

0%

NS

Cont_13

273

830

ACA_lo

147

918

11%

<0.0001

1,211

11%

0.0004

ACA_mid

161

975

17%

<0.0001

1,210

11%

0.0004

ACA_hi

163

964

16%

<0.0001

1,181

8%

0.0001

UA

151

883

6%

0.38

1,092

0%

0.91

Cont_12

284

816

HBX

155

822

1%

0.4

1,069

1%

NS

I767d

147

791

–3%

0.11

1,012

–4%

NS

1,100

Males
1,089

1,055

Note. Lifespans of ITP mice from cohorts 2013 and 2012. Cont_13 = controls for cohort started in 2013; Cont_12 = controls for cohort started in
2012. N = number of mice tested; data were pooled, with about 1/3 from each testing site. Probabilities that lifespans are the same as the controls in
column 4 (p‐value) used two‐tailed log‐rank test on pooled data stratified by sites; “removed” mice were included in these calculations. Probabilities that
the proportion of live mice is the same in treated as in the control group at the 90th percentile age are evaluated by the procedure of Wang et al.,
(2004). Amounts of ACA in diet: hi = 2,500 ppm; mid = 1,000 ppm; lo = 400 ppm. UA, HBX, and 1767d had no significant effect on lifespan in the
doses used.
NS: not significant.
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F I G U R E 1 Effects of ACA on lifespan and body weight. Effects of dietary ACA dose on: (a, b) lifespans; (c, d) body weights over lives of
the same mice. Lifespan curves (a and b for females and males) show the entire lifespan from the data used to produce Table 1, which
includes sample sizes and statistical analyses of differences in median and 90th percentile values from the control as a result of each ACA
dose. Body weights (c and d for females and males) represent 115–165 mice tested at 6, 12, 18, and 24 months of age in the ACA‐fed groups.
Numbers of controls were about twice as high. Using one‐way ANOVA with Sidak post hoc test, there was no effect of ACA at 6 months. At
12 and 18 months, weights were significantly different as shown by >: Males – Control, ACA_lo > ACA_hi, ACA_mid; Females –
Control > ACA_lo > ACA_mid, ACA_hi. At 24 months of age, there were no significant differences between Control and treated males, while
in Females – Control, ACA_Lo > ACA_hi, ACA_mid. Weights at 24 months are hard to interpret, due to unbalanced death rates at the three
sites, and possible weight loss due to ill health

T A B L E 2 Effects of ACA on median lifespan at each ITP site
TJL
Group

Days

UM
% change

p‐value

Days

UT
% change

p‐value

Days

% change

p‐value

Mean % change

Females
Cont_13

890

870

897

ACA_lo

887

0%

0.43

871

0%

0.49

923

3%

0.03

1%

ACA_mid

934

4%

0.33

890

1%

0.06

950

4%

0.02

3%

ACA_hi

938

6%

0.13

931

6%

0.32

917

2%

0.03

5%

Males
Cont_13

803

ACA_lo

880

10%

0.001

912
924

1%

0.21

807
919

14%

0.0006

8%

ACA_mid

967

20%

0.000

1,033

13%

0.006

914

13%

0.002

16%

ACA_hi

960

20%

0.000

975

7%

0.21

957

19%

0.000

15%

Note. For each site, this table lists median lifespans, % change, and the log‐rank p‐value from the control (Cont_13) for mice fed the three different
doses of ACA starting at 8 months of age. A p‐value of 0.000 means p < 0.001. The rightmost column shows averages (“Mean % change”) of median
changes across the three sites.

three doses of ACA increased lifespan significantly at TJL and UT

13, 19) than at UM (1, 13, 7), perhaps reflecting the 14% longer lifespan

(p = 0.002 to <0.0001); only the 1,000 ppm dose gave a significant

of control males at the UM site. As in past ITP cohorts, lifespan for con-

increase in male lifespan at UM (p = 0.006). Percentage increases in

trol females was similar at all three sites (median values at TJL—

lifespan—given for diets containing 400, 1,000, and 2,500 ppm ACA,

890 days, UM—870 days, and UT—897 days), but longer for males at

respectively, in Table 2—also were larger at TJL (10, 20, 20) and UT (14,

UM (TJL—803 days, UM—912 days, and UT—807 days).

HARRISON
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Using pooled data from the same mice, when fed 1,000 or

weights by 8–12 g in females at 12–22 months of age (Figure 2a),

2,500 ppm ACA, body weights averaged 4–6 g lower in females at

and by 6–8 g in males over the same age range (Figure 2d). The

12, 18, and 24 months of age (Figure 1c) and 2–4 g lower in males

decrease in % female body fat (Figure 2b) was about twice as great

at 12 and 18 months of age (Figure 1d). Statistically, female controls

as in males (Figure 2e), while the increase in % lean mass in females

were the heaviest at 12 and 18 months, with females fed 400 ppm

fed ACA (Figure 3c) was two to three times greater than in males

ACA next most heavy. Those fed 1,000 or 2,500 ppm ACA were the

(Figure 2f).

lightest, with similar body weights (Figure 1c). At 12 and 18 months,

A separate set of data from UM defined the effects of ACA

male controls and those fed 400 ppm ACA were the most heavy,

feeding on four fat depots using HET3 mice at 12 months of age

while those fed 1,000 or 2,500 ppm ACA were lighter, and not sig-

(Figure 3). In subscapular fat, there were no ACA effects in females,

nificantly different from each other (Figure 1d).

but highly significant effects in males (p < 0.001). In mesenteric fat,
ACA caused highly significant reductions in both sexes (both
p < 0.001). In gonadal fat, ACA effects were also similar in both

2.2 | Body composition

sexes, but did not reach statistical significance, and in inguinal fat,
ACA had no effect (Figure 3).

Acarbose at 1,000 ppm was fed to separate groups of mice starting
at 4 months of age, and weights and body composition then evaluated at two sites. At TJL and UT, fat and lean weights were mea-

2.3 | Pathology

sured by NMR body composition analysis, using the echo MRITM 3‐
in‐1 (Table 2), in which grams of fat are the mass of the body's fat

As illustrated in Figure 4, males fed ACA had about half as many lung

molecules expressed as g of canola oil, while grams of lean are mus-

tumors as controls, but ACA feeding did not reduce the already low

cle tissue mass equivalent of all body parts containing water, exclud-

frequency of lung tumors in females. The frequency of adrenal

ing fat, bone, and substances that do not contribute to the NMR

medullary vasodilation was reduced to an equivalent extent in both

signal, such as hair, teeth, and claws. Testing the same groups of

sexes, reaching statistical significance in females, and in the pooled

ACA‐fed and age‐ and sex‐matched control mice at 16–17, 22–23

data, though not in males (Figure 4). Replicating results reported by

and 29–30 months of age, ACA reduced body and fat weights signif-

Strong et al. (2016), ACA reduced the incidence of liver degeneration

icantly in females, but had no significant effects on these measures

in both male and female UM‐HET3 mice, but only results in males

in males. Lean mass was not affected by ACA in either sex (Table 2).

and the pooled population were significant. Finally, females fed ACA

At UT, ACA diets also had greater effects in females, reducing body

had less glomerulosclerosis, but not males in which glomerulosclerosis

Female weight

Female % body fat

60

55
50
45
40
35

40
30
20
10
0

30
120

240

360

480

120

Age (days)

Fat (% body mass)

Body weight (g)

240

360

480

55
50
45
40
35
30
240

360

480

Age (days)

65
60
55
0

120

(e)

50

600

40
30
20
10

0

120

240

360

Age (days)

240

360

480

600

Age (days)

0
120

70

600

Male % body fat

60

(d)

0

75

Age (days)

Male weight
60

(c)

80

50
0

600

Lean mass (% body mass)

0

Female % lean mass

85

(b)

50

Fat (% body mass)

(a)

Fat (% body mass)

Body weight (g)

60

480

600

Male % lean mass
85

(f)

80
75
70
65
60
55
50
0

120

240

360

480

600

Age (days)

F I G U R E 2 Changes with age in body composition due to dietary ACA. Effects of 1,000 ppm ACA diet starting at 8 months of age on
weights and body composition from 8 to 22 months of age at UT. Giving numbers of mice at 8–22 months of age: females (32–28 controls,
32–28 ACA‐treated); males (32–14 controls, 33–30 ACA‐treated). The same groups of mice were tested at 8, 12, 16, 20, and 22 months. ACA‐
treated have blue dots; controls black dots. Data are shown as mean ± SE, and weights and body fat were significantly lower, while lean mass
was significantly higher in both males and females fed the ACA diet as measured by 2‐way ANOVA using GraphPad version 7.03, which
accounted for the missing mice

6 of 13
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F I G U R E 3 Effects of ACA on fat depends on specific fat type. Effects of ACA on amount of fat relative to body weight in 12‐month‐old
HET3 mice at UM. Numbers of male ACA and controls are 9 each, while 8 females received ACA and 6 were controls. In subscapular fat, ACA
effects are sex‐specific: females, p = 0.71; males, p < 0.001. In mesenteric fat, ACA results in a strong reduction in both sexes: p < 0.001. In
gonadal fat, ACA effects are similar in both sexes, but weak: p = 0.074. In Inguinal fat, ACA has no effect. p values, from analysis of
covariance, reflect differences in the intercept term, which measures whether ACA alters fat pad weight after adjustment for body weight.
HET3 mice were fed diet with 1,000 ppm ACA starting at 4 months; controls were fed the base diet. Mice were fasted for 18 hr prior to
dissection. This was part of a larger study in which mice had a sham‐operation procedure at age 3 months. They were anesthetized, gonads
were exteriorized through an incision and then returned to the abdominal cavity, and the wound closed

was rare even in controls (Figure 4). Lesions that were not affected

(p = 0.0001), while male mice did not show significant benefits. Young

by ACA feeding, to a significant degree, included endometrial hyper-

female controls performed better than old controls (p = 0.02), while

plasia, lymphoma, pancreatic atrophy, renal mineralization, adrenal

untreated males showed the same trend but it was not statistically sig-

hyperplasia, adrenal cortical degeneration, hepatic microgranuloma,

nificant (p = 0.06). In a second measure of performance—mean latency

uterine cysts, uterine cystic endometrial hyperplasia, ovarian atrophy,

to fall averaged over the 6‐days—female mice fed ACA again per-

and ovarian pigment/lipofuscin; inferences about these negative find-

formed better than age‐matched controls (p = 0.02), and young female

ings would require confirmation using a larger number of test cases.

controls performed better than old controls (p = 0.006). Again, ACA did
not lead to significant improvement in male mice, although young male

2.4 | Blood glucose after refeeding

controls performed better than old (p = 0.007). In a measure of learning
rate, the rate of change across the 6‐day training period, ACA‐fed

Figure 5 shows young (4 month old) males and females that were

females again performed better than age‐matched controls (p = 0.009),

fed either control diets (0 ppm ACA) or diets containing 400, 1,000,

and again, old female controls performed less well than young

or 2,500 ppm ACA for 6 weeks. Food was removed at 6 p.m., and

(p = 0.01). Male learning rates did not differ among younger controls,

returned at 9 a.m. the next day. Blood glucose levels were measured

ACA‐treated, or old controls (all p > 0.05).

just before food was returned, and 30, 60, 180, and 360 min after it
was returned. There were no significant differences in females, but
highly significant (p < 0.002) differences in males, in which higher
levels of ACA in diets reduced blood glucose after refeeding.

2.5 | Rotarod performance with training

3 | DISCUSSION
3.1 | Effects of ACA on lifespan, weight, and body
composition
Key findings are that ACA improves male lifespan over a broad

Rotarod testing was conducted, and average performance by sex,

range, with significant effects from diets containing 400, 1,000, or

group, and day is shown in Figure 6. On test day 6, after 5 days of

2,500 ppm ACA. At all three doses, ACA extended lifespan much

training, ACA females performed better than age‐matched old controls

more strongly in males than in females (Tables 1 and 2), offering an

HARRISON
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F I G U R E 4 Microhistopathology effects
of ACA. Lesions are compared in controls
and mice fed the 1,000 ppm ACA diet
starting at 4 months of age. Numbers of
mice: ACA old – 57 F and 54 M. The
Control group consisted of 41 male and 43
female animals, of which 11 males and 14
females were contemporaneous with the
current ACA population, and the remainder
consisted (as a preplanned strategy) of
controls from earlier cohorts also evaluated
at 22 months of age. About a third of the
mice came from each site. The values
shown are percentage of cases with the
indicated lesions, and p‐values reflect
differences between two proportions using
an asymptotically, normally distributed z
statistic, as documented in the STATA
program
interesting model for sex differences. In Figure 5, ACA affects daily

activity (Harrison et al., 2014), showing that these treatments differ.

postprandial increases in glucose much more in males than in

Effects of ACA and DR may differ in HET3 mice due to carbohy-

females, so males may be more amenable to metabolic benefits from

drate vs. total diet restriction. Differences could reflect differences

ACA. Most UM‐HET3 mice die with some form of cancer, so ACA

in the microbiome (Smith et al., 2018) caused by the different treat-

effects on overall lifespan probably reflect protection against neo-

ments, or factors still to be elucidated.

plastic disease.

Besides ACA, significant increases in male lifespans are caused

As in previous ITP cohorts (Harrison et al., 2009, 2014; Miller

by 17‐α‐estradiol (17aE2), aspirin, Protandim, and nordihydrogua-

et al., 2011, 2014; Strong et al., 2008, 2016), unknown site‐specific

iaretic acid (NDGA) (Harrison et al, 2014; Strong et al., 2008, 2016)

differences led to male control mice living longer at UM than at UT

and by rapamycin in both male and female mice (Harrison et al.,

and TJL. Female controls in the same cohorts had very similar lifes-

2014, 2009; Miller et al., 2011, 2014; Wilkinson et al., 2012). Rapa-

pans at all three sites. This offers opportunities to explore sex‐speci-

mycin also improves type II diabetic models (Reifsnyder et al., 2015,

fic aspects of aging.

2016, 2017) and brain histone modifications (Gong et al., 2015).

If the longevity benefit of ACA were due strictly to its effects on

Effects with 17aE2 may be explained by metabolomic responses

weight and fat, one might expect that its lifespan benefit would be

modulated by gonadal hormones (Garratt, Tsai, Galecki, Jain, &

stronger in females than in males, contrary to our findings. Weights

Miller, 2018).

were reduced more in females than in males (Figure 1c,d), as were
amounts of fat (Table 2, Figure 2). Thus, the lengthened survival for
ACA‐treated males vs. ACA‐treated females cannot be explained

3.2 | Specific physiological effects of ACA

solely by changes in body weight or fat, suggesting that the ACA

Further key findings are from detailed studies of ACA‐treated and

benefit on lifespan is not directly due to the effects of diet restric-

control mice at each site. At UM, effects of ACA on amount of fat

tion (DR), which increases male and female lifespans to a similar

relative to body weight in 12‐month‐old HET3 mice differ greatly

degree in HET3 mice (Flurkey et al., 2010). Furthermore, ACA and

depending on which fat type is examined (Figure 3). In only one fat

DR have opposite effects on blood levels of FGF21 and on voluntary

type, subscapular, are ACA effects sex‐specific, with no effects in

8 of 13
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F I G U R E 5 ACA effects on blood glucose after refeeding. Postprandial blood glucose is reduced in males but not in females by 6 weeks on
ACA diets. Male and female UM‐HET3 mice were given one of four diets for 6 weeks starting at 4 months of age. Each point represents the
mean ± SEM of 10 mice, tested at the indicated times. Green symbols indicate diets formulated with ACA at 2,500 ppm; blue 1,000 ppm; red
400 ppm; and white 0 ppm (control). Mice were fasted from 18:00 until 9:00 the next day. Blood glucose was measured at “0” min (before
food was returned), and at 30, 60, 180, and 360 min after the food was returned to their cages. All measures were made in each sex in a
single session, but in different sessions for each sex. Data were analyzed using RM one‐way analysis of variance (ANOVA) for male and female
mice separately. In both sexes, we compared the differences between the four groups using GraphPad Prism 7.03. In females, the different
diets did not affect blood glucose levels significantly (p = 0.092). In males, the different diets had significant effects on blood glucose
(p = 0.002)
females and a highly significant reduction of fat relative to body

significant in females but not in males (Figure 6). These data suggest

weight in males. Perhaps subscapular fat might be important in pre-

that lifespan measures do not detect the advantage given by ACA to

dicting effects of drugs on lifespan, although tests at a wider variety

females in the agility tested by the rotarod.

of ages and with a wider variety of interventions are essential before
concluding this is the case.

The National Institute on Aging Interventions Testing Program
(ITP) has previously reported significant increases in lifespan caused

Figure 4 presents pathology of mice, 22–25 months of age,

by aspirin, Protandim, and nordihydroguaiaretic acid (NDGA) in male

which had been fed 1,000 ppm ACA (57 F and 54 M) and three

mice (Strong et al., 2008, 2016) and by rapamycin in both male and

pooled groups of age‐matched controls (43 F and 41 M). HET3 mice

female mice (Harrison et al., 2014, 2009; Miller et al., 2011, 2014;

show a wide range of lesions, making them a good model for normal

Wilkinson et al., 2012). Rapamycin also improves type II diabetic

populations, but the sparse distribution of many specific lesions

models (Reifsnyder et al., 2015, 2016, 2017) and brain histone modi-

among 22‐ to 25‐month‐old HET3 mice limits statistical power for

fications (Gong et al., 2015). Acarbose and 17‐α‐estradiol (17aE2)

specific pathologies. Nevertheless, 37% of male controls had lung

also extend mouse lifespans, with stronger (ACA) or exclusive

tumors, and ACA reduced this by half, which might explain some of

(17aE2) effects in males (Harrison et al., 2014; Strong et al., 2016).

the increase in male lifespans.

Effects with 17aE2 may be explained by metabolomic responses

In fasting and refeeding assessed at UT (Figure 5), glucose levels

modulated by gonadal hormones (Garratt et al., 2018).

were not affected by ACA in females, but were effects in males were

The lifespan studies of the ITP show that adhering to rigorous

highly significant, and higher amounts of ACA led to lower levels of

standards provides strong evidence that mouse lifespan can be repro-

blood glucose. This test was done using mice at 5.5 months of age,

ducibly extended by drugs in the diet (Harrison et al., 2009, 2014;

which had been fed ACA for only 6 weeks. While it suggests a reason

Miller et al., 2011, 2014; Strong et al., 2008, 2016; Wilkinson et al.,

for larger effects on male lifespans, effects of ACA should be tested

2012). The growing arsenal of drugs that extend lifespan, perhaps by

over longer periods of time. Lamming et al. (2013) showed no signifi-

modulation of aging, cancer, or both, provides raw material for mecha-

cant decrease of insulin sensitivity or increase in glucose with age in

nistic studies. It also will complement work done using mutant stocks

either male or female HET3 mice, but these were average numbers

and dietary interventions to delineate the factors that control aging

taken during the day when mice were not eating; it is possible that

rate in mammals and link aging to multiple forms of illness.

postprandial surges in blood glucose may have effects on health and
lifespan independent of mean levels of glucose. Hormones of the
gonadal–pituitary axis may be important in sex differences. Yuan et al.
(2012) showed that female sexual maturation co‐regulated with lifespan via IGF1, while Garratt, Bower, Garcia, and Miller (2017) showed
that gonadal hormones were important in differences between males

4 | EXPERIMENTAL PROCEDURES
4.1 | Mouse production, maintenance, and
estimation of lifespan

and females on several effects of ACA, including glucose homeostasis,

UM‐HET3 mice were produced at each of the three test sites as pre-

although endocrine effects on lifespan were not evaluated. Benefits of

viously described (Harrison et al., 2009; Miller et al., 2011; Strong

ACA on rotarod performance (Jones & Roberts, 1968) are highly

et al., 2008), where environmental conditions are presented in detail.

HARRISON
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F I G U R E 6 Effects of ACA on rotarod performance. Training on a rotarod was more effective in females fed ACA, but there was no benefit
in males. Groups of male and female UM‐HET3 mice were fed control or acarbose‐containing diets (1,000 ppm) beginning at 8 months of age
until they were 22 months of age. A group of 4‐month‐old mice fed the control diet served as the young control group. Mice were trained on
a rotarod for 5 days, with a final test done on day 6, and the latency to fall was tested. Average performance is shown by treatment, day, and
sex. Error bars represent standard errors of the means. Sample sizes for female mice were as follows: young control = 19, ACA‐fed = 27, and
old control = 27; and for male mice: young control = 19, ACA‐fed = 29, and old control = 14. Since mice with lower weights tended to have
higher rotarod times, weight was regressed onto group, and the residuals from this model used to adjust for weight in an ANCOVA comparing
averages between groups (young vs. acarbose vs. untreated)
The dams of the test mice were CByB6F1/J, JAX stock #100009

with no significant site differences. For details, see Methods to cen-

(dams, BALB/cByJ; sires, C57BL/6J). The sires of the test mice were

sor mice for lifespan statistics, Supporting Information Appendix S1.

C3D2F1/J, JAX stock #100004 (dams, C3H/HeJ; sires, DBA/2J). In
each site, breeding mice were fed LabDiet® 5008 mouse chow (PMI
Nutritional International, Bentwood, MO, USA). As soon as mice

4.3 | Estimation of age at death (lifespan)

were weaned, they were fed LabDiet® 5LG6 from the same source.

At UM and UT, mice were examined daily for signs of ill health from

Males were initially housed 3 per cage, while females were housed 4

the time they were set up in the experiment. At TJL, once mice were

per cage; numbers declined as mice died.

marked as ill, they were examined daily for signs of ill health. Mice

Details of the methods used for health monitoring were provided

were euthanized for humane reasons if so severely moribund that

previously (Harrison et al., 2009; Miller et al., 2011; Strong et al.,

they were considered, by an experienced technician, unlikely to sur-

2008). In brief, each of the three colonies was evaluated four to

vive for more than an additional 48 hr. The TJL definitive endpoint

twelve times each year for infectious agents. All such surveillance

criterion is the nonresponsiveness of a mouse to being touched, and

tests were negative for pathogens at all three sites throughout the

which is usually accompanied by one or more of the following: slow

entire study period.

respiration, feeling cold to the touch, a hunched‐up appearance with
matted fur, and signs of sudden weight loss, failure to eat and drink,

4.2 | Removal of mice from the longevity
population
Mice were removed from the study because of fighting or accidental

prominent appearing ribs and spine, and sunken hips.
The age at which a moribund mouse was euthanized was taken
as the best available estimate of its natural lifespan. Mice found
dead were also noted at each daily inspection.

death (e.g., during chip implantation) or chip failure, or because they
were used for another experimental purpose. For survival analyses,
all such mice were treated as alive at the date of their removal from

4.4 | Control and experimental diets

the protocol and lost to follow‐up thereafter. These mice were not

Studies with diets done at similar times are reported here, as even

included in calculations of median longevity. Overall, <3% of the

the diets with no effects act as useful controls. TestDiet®, Inc., a

mice were removed from the longevity populations reported here,

division of Purina Mills (Richmond, IN, USA), prepared batches of

10 of 13
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LabDiet® 5LG6 food containing each test substance, as well as con-

details, see: Measuring amounts of Interventions, Supporting Infor-

trol diets, at intervals of approximately 4 months, and shipped each

mation Appendix S1.

batch of food to the three test sites.
1. ACA or Acarbose was purchased from Spectrum Chemical Mfg.

4.6 | Measures of body composition

Corp., Gardena, CA, product # A3965, CAS # 56180‐94‐0. It was

At TJL, a Nuclear Magnetic Resonance (NMR) Imaging Instrument

fed continuously at a concentration of 400, 1,000, or 2,500 mg

(EchoMRI™ 3‐in‐1, EchoMRI LLC, Houston, TX, USA) was used to

of ACA per kilogram of diet (ppm) to a test group of mice from

measure body composition of fat, lean, free water, and total water

cohort 2013 starting at 8 months of age. In independent groups

masses. Subjects were placed in a restrainer tube (nonanesthetized),

of mice, it was fed at 1,000 mg/kg starting at 4 or 8 months of

and three consecutive scans, 2 min in duration, were taken sequen-

age, as indicated. Probably amounts of ACA were about a third

tially, and data were averaged for each subject. The fat calculation is

of expected in the diet, as average concentration of acarbose in

measured as total body fat inclusive of organ and tissue fat and fatty

5 batches of food pellets was 231 ± 109 (SD) ppm (intended

acids. Lean mass is muscle plus all organs. At UT, mice were placed

dose 1,000 ppm). A primary effect of acarbose is to reduce

in a plastic cylinder (4.7 cm ID, 0.15 cm thick) in a qMRI machine

postprandial glucose plasma levels in humans (Ruppin et al.,

(EchoMRI, Echo Medical Systems) and scanned once for 2 min. Data

1988). We observed the same result as an outcome measure in

at both sites are expressed as % of body mass.

this study (Figure 5). The combination of these results indicates
that the same pharmacokinetic and pharmacodynamic effects of
acarbose were achieved with our study design. For details, see:

4.7 | Pathology

Information

Using standard microhistopathological methods, J. Erby Wilkinson, a

2. UA or Ursolic acid was obtained from Wilshire Technologies,

UM‐HET3 mice: 57 females and 54 males had been fed a

Princeton NJ, CAS # 77‐52‐1. It was fed continuously at a con-

1,000 ppm ACA diet since they were 4 months old. There were 14

centration of 2,000 ppm to a test group of mice from cohort

female and 11 male controls set up at the same time, plus two previ-

2013 starting at 10 months of age.

ous groups of age‐matched UM‐HET3 controls, for a total of 43

Experimental

diets—Acarbose,

Supporting

Appendix S1.

board‐certified veterinary pathologist, examined 22‐ to 24‐month‐old

3. HBX or 2‐(2‐hydroxyphenyl) benzothiazole was obtained from

females and 41 males not fed ACA. Evaluation of the ACA mice and

Sigma Aldrich, Inc., St Louis, MO, USA, product # H50802, CAS

the new set of age‐matched controls was conducted in a blinded

# 835‐64‐3. It was fed continuously at a concentration of 1 ppm

fashion, and the data from the old control mice combined with prior

to a test group of mice from cohort 2012, starting at 15 months

records compiled by Dr. Wilkinson on earlier cohorts of untreated

of age. In pilot studies, diets designed to contain 1 and 10 ppm

UM‐HET3 mice for statistical purposes.

HBX had 85% and 83% of expected amounts, respectively.
Serum of mice fed 1 ppm HBX for 8 weeks had serum levels of
89–252 ng/ml HBX, pilot mice fed 10 ppm HBX for 8 weeks had

4.8 | Refeeding effects on blood glucose

<50 to 316 ppm, with no significant differences in serum levels

Ten HET3 mice in each group were given one of four diets for

between the two groups, so 1 ppm HBX was used in the full

6 weeks starting at 4 months of age; the diets contained 2,500 ppm,

lifespan study.

1,000 ppm, 400 ppm, or 0 ppm of ACA. Mice were then fasted from

4. I767d, INT‐767 or 6α‐ethyl‐24‐nor‐5β‐cholane‐3α,7α,23‐triol‐23

18:00 to 09:00 the next morning. Tail vein blood was sampled

sulfate sodium salt was obtained from WIL Research, Inc., Ash-

(around 50 microliters) at “0” minutes before returning food, and

land OH (in 2016 it was renamed Charles River Laboratories,

again 30, 60, 180, and 360 min after the food was returned.

Ashland), and the material was a proprietary product. It was fed

Amounts of glucose were measured in each blood sample using a

continuously at a concentration of 180 ppm to a test group of

blood glucose meter One Touch Ultra Blue (Life‐Scan, Milpitas, CA,

mice from cohort 2012 starting at 10 months of age. In pilot

USA).

studies, the amount of INT‐767 in the diet was 73% of the
180 ppm expected. After 8 weeks of diet containing INT‐767,
amounts in serum ranged from 254 to 869 ng/ml while control
serum contained less than 1.5 ng/ml.

4.9 | Rotarod
Rotarod performance was tested using the Rotamex‐5 (Columbus
Instruments, Columbus, OH, USA) for 6 consecutive days by a tech-

4.5 | Measuring amounts of interventions

nician who was blinded to the treatment groups. Testing on each
day consisted of eight trials with a 10‐min rest between trials 4 and

Assays for acarbose, HBX, and I767 were done at UT. The initial

5. Each trial began with the rotarod set at an initial rate of 4 rpm,

drug material, food pellets, and mouse serum were sampled, pre-

accelerating to a maximum 40 rpm within 300 s. The latency to fall

pared, and assayed as detailed in the material published here on line.

was recorded by the Rotamex‐5 software, and the average latency

Samples were quantified using HPLC with ultra violet detection. For

to fall was calculated for each day.
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T A B L E 3 Effects of ACA on weight and body composition at TJL
Group

Body weight
(g)

Females

17 months

Control

44 ± 2

ACA

33 ± 2**

Males

16 months

Fat weight
(g)

Lean weight
(g)

Body weight
(g)

Fat weight
(g)

Lean weight
(g)

23 months

Body weight
(g)

Fat weight
(g)

Lean weight
(g)

29–30 months

17 ± 2

21 ± 1

43 ± 3

15 ± 3

21 ± 1

37 ± 3

8±3

23 ± 1

7 ± 1**

21 ± 1

36 ± 3

8 ± 2*

21 ± 2

29 ± 2*

2 ± 1*

20 ± 2*

22–23 months

29–30 months

Control

42 ± 2

8±2

26 ± 3

42 ± 4

9±3

21 ± 1

34 ± 3

3±2

24 ± 2

ACA

42 ± 1

7±1

25 ± 2

41 ± 2

7±2

21 ± 2

35 ± 1

2±1

27 ± 1

Note. Mice were tested using the EchoMRI™ 3‐in‐1. The ages of the mice are given for each sex. ACA‐treated mice were fed ACA at 1,000 ppm starting at 4 months of age. The mice tested were not the same mice used for lifespan studies. Statistical tests were a two‐way repeated measures ANOVA.
Numbers of HET3 mice tested at 16–17, 22–23 and 28–29 months—Females: ACA‐treated (12, 9, 4); Controls (14, 13, 5). Males: ACA‐treated (20, 18,
14); Controls (9, 4, 4).
**Control differs from ACA‐fed p < 0.0001. *Control differs from ACA‐fed p = 0.04 to 0.01.

4.10 | Statistical methods
Significance tests about survival effects are based upon the two‐

Research and Development. We wish to thank Peter Reifsnyder,
Pam J. Krason, Vicki Ingalls, Natalie Perry, Lori Roberts, Roxann
Alonzo, Ilkim Erturk, Nelson Durgin, and Vivian Diaz for reliable

tailed log‐rank test at p < 0.05, stratified by test site, with censored

technical assistance, and The Jackson Laboratory's Center for Bio-

mice included up until their date of removal from the longevity pop-

metric Analysis for core services including generation of the NMR

ulation. Data from male and female mice are considered separately.

data.

In statistical tests described in the text, p values are two‐tailed and
reported without adjustment for multiple comparisons, except in Figure 6. Statistical claims related to maximum lifespan are based on
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4.11 | Figure 6 statistics

statistical lifespan analyses. SJSR did physiological assays at TJL. GM
provided data and analysis for Figure 3. JALG did statistical analysis

For statistical analysis of the rotarod performance, the average of

of rotarod performance and advised on statistical analysis of

time‐to‐fall sessions for each animal on each day (1–6) was consid-

postprandial glucose and body composition at UT. FM served as the

ered as a repeated measure in a mixed‐effect linear model with a

project officer for the National Institute on Aging and contributed to

random intercept for males and females separately and estimated

program development, experimental design and analysis. EF super-

the main effects of day, group (Old Control, Old ACA, and Young

vised laboratory personnel and data collection at the UTHSCSA site.

control), and the group‐by‐day interaction. We compared the pair-

JEW conducted the pathology analysis. MAJ supervised assays at

wise differences between the three groups and adjusted for multiple
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testing using Tukey's Honest Significant difference method (HSD).
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For details, see Statistical methods—Figure 6 statistics Supporting
Information Appendix S1.
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